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A 56 year old retired theatre nurse who has metastatic breast carcinoma complains of reduced vision in
the left eye since being started on Docetaxel (Taxotere), an oral anti-mitotic chemotherapeutic agent.
Best corrected visual acuity was 6/18 in the left eye, and 6/9-1 in the right. Clinical examination and
subsequent examination with optical coherence tomography and Intravenous Fluorescein angiography
revealed evidence suggestive of drug related maculopathy. No abnormal ﬁndings were present in the
right eye. As far as we are aware, this is the ﬁrst reported case of maculopathy following commencement
of Docetaxel with the absence of macular oedema.
& 2016 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Clinical practice points– Docetaxel is of the chemotherapy drug class taxane.
– Mainstay of use is for breast cancer, prostate cancer, and non-
small cell lung cancer.
– Main dose-limiting adverse effect of this agent is toxicity to bone
marrow, though also associated with ﬂuid retention syndrome
consisting of peripheral oedema and/or pleural effusion.
– First documented case of non-oedematous maculopathy.
– Patients started on Docetaxel therapy should be counselled for
possible drug associated toxic maculopathy, and that this should
be considered in all patients complaining of visual disturbance.2. Case report
A 56 year old retired theatre nurse under the care of the on-
cologist for the treatment of advanced breast cancer is referred to
our ophthalmology department after complaining of deteriorating
vision particularly effecting the left eye. The patient has extensive
lymph node and liver metastases for which she is on palliative oral
chemotherapy in the form of the anti-mitotic Docetaxel (Taxotere),
mainly used in the treatment of breast, ovarian, prostate, and non-
small cell lung cancer.
The patient was initially diagnosed with breast cancer ins article under the CC BY-NC-ND lDecember 2009, and underwent a mastectomy soon afterwards.
Metastatic spread was discovered in July 2012, and chemotherapy
was subsequently initiated in August 2012, on a combination of
Docetaxel and steroid. Soon after commencement, the patient
began to notice that her vision was starting to deteriorate, with a
distinct lack of clarity. The patient initially ignored the symptoms,
but in early 2013 visited her opticians felt some changes at the
macula were present. It was at this stage that the Oncologists re-
ferred the patient for an Ophthalmology opinion, mainly to rule
out the presence of choroidal metastases.
The patient's chemotherapeutic treatment plan consisted of
monthly intravenous infusions of 100 mg/m2 of docetaxel. The
patient was on no other concurrent medication, and there was no
history of tamoxifen use during the period of chemotherapy.
On presentation to the Ophthalmology department, her initial
visual acuity was recorded at 6/9-1 in the right eye, and 6/24 in the
left (improvement to 6/18 pin-hole). Intraocular pressures were
within normal limits. Anterior segment examination was un-
remarkable, and dilated fundal examination revealed no evidence of
vitritis. Dry macular changes were noted in the left eye indicative of
toxicity (Fig. 1). This was conﬁrmed on optical coherence tomo-
graphy (Stratus OCT; Carl Zeiss Meditec, Dublin, CA, USA). Fluor-
escein angiography exhibited normal ﬁlling of the choroidal and
retinal vessels and an intact parafoveal capillary net, and no evi-
dence of leakage on late frames (Fig. 2). Electrodiagnostic testing
was carried out to conﬁrm macular dysfunction (Fig. 3).
The patient denies any past ocular history of note, and has
never undergone any intraocular surgery, or ever taken pros-
taglandin eye drops. Of note in her medical history, the patient is
Factor XI deﬁcient. She does not suffer from diabetes. There is no
familial ocular history of note.icense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Fundal photographs displaying Retinal Pigment Epithelium atrophy and hyperpigmentation in an almost “bullseye” pattern in both maculae.
Fig. 2. Intravenous Fluorescein angiography exhibited normal ﬁlling of the choroidal and retinal vessels and an intact parafoveal capillary net, with no evidence of leakage on
late frames.
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genital X-linked retinoschisis were unlikely other differential di-
agnosis, given the history of onset and ﬁndings on clinical
examination.3. Discussion
Docetaxel is of the chemotherapy drug class taxane, and is a
semi-synthetic analogue of paclitaxel (Taxol), an extract from the
bark of the rare Paciﬁc yew tree Taxus brevifolia, and acts by in-
ducing microtubular stability and disrupting the dynamics of the
microtubular network [1]. The mainstay of use is for breast cancer,
prostate cancer, and non-small cell lung cancer. Dosage varies
from 60 to 100 mg/m2 administered as an infusion every 3–4
weeks [2]. The main dose-limiting adverse effect of this agent is
toxicity to bone marrow. Docetaxel has also been associated with
ﬂuid retention syndrome consisting of peripheral oedema and/or
pleural effusion. Ophthalmic adverse effects include decreased
vision, scintillating scotomas, and abnormal visual evoked poten-
tials [3].
There are ﬁve documented cases of maculopathy secondary to
paclitaxel in the literature, some of which were treated success-
fully with acetazolamide administration [4–7]. This would only be
effective however if there was the presence of ﬂuid in the macular;
i.e. the presence of a cystoid macular oedema. In our case however,
acetazolamide would have no effect given the absence of any
macular oedema, and to our knowledge, the only other reported
case of maculopathy secondary to Docetaxel alone was cystoid in
appearance (there is one report of simultaneous docetaxel-in-
duced cystoid macular oedema in both eyes, but this was in the
presence of systemic ﬂuid retention syndrome secondary to doc-
etaxel, and is therefore the result of a systemic mechanism) [2,8].
The authors in the prior literature have hypothesised that the
occurrences may have been either as a result of intracellular ﬂuidaccumulation and the slight leakage of extracellular ﬂuid caused
by toxicity to Muller cells [4], or due to the fact that that the
passage of ﬂuid increases in the capillary due to ﬂuid retention
syndrome, which causes oedema and protein leakage of the ca-
pillary [8]. This results in cystoid macular oedema occurs due to
selective damage of the blood ocular barrier frommolecules with a
weight less than that of ﬂuorescein or to slow ﬂuid movement that
cannot be detected on ﬂuorescein angiography [8].
With our patient, there was no evidence of any retinal traction,
or any underlying diseases that may cause a maculopathy. Given
the fact that, unlike in the other reported cases, there was no
evidence of a systemic ﬂuid retention syndrome, the observed
maculopathy is probably a result of cellular toxicity derived from
the suppression of intracellular microtubule reorganisation [5].
The patient was on no other medication known to cause macular
disease, bar steroid treatment-this however would not result in
the dry macular changes that were found, and therefore not re-
sponsible [9]. On the Naranjo adverse drug reaction probability
(ADR) scale, we would grade this ADR as “probable”, based on a
score of 6 (on the basis of previous conclusive reports, the fact that
the ADR occurred after commencement of the drug, the absence of
alternative causes, and the conﬁrmation of the ADR with objective
evidence).
Although the maculopathy is currently limited to one eye, with
longer term administration, it is likely that the other eye will
probably become involved. This has already been shown to be the
case with paclitaxel, with subsequent contralateral eye involve-
ment in due course with continuing treatment. In the above-
mentioned literature, chemotherapy stopped at the advent of cy-
stoid macular oedema; our patient however, opted to persevere
with chemotherapy. Unfortunately the patient succumbed to the
breast cancer very soon after being seen by the Ophthalmology
team; we are therefore unable to comment on the progression or
otherwise of the maculopathy under continuous Docetaxel
treatment.
Fig. 3. Pattern Electroretinograms (ERG) were consistent with macular dysfunction, marked for the left eye, subtle for the right. Multifocal ERGs show this to be in the form
of a well demarcated area of reduced cone function affecting the central 7° or so for the left eye, extending to include the blind-spot; there is evidence of similarly distributed
dysfunction affecting the right eye as well, although this is much less marked. Flash ERGs show no evidence of more diffuse retinal dysfunction.
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As far as we are aware, this is the ﬁrst reported case of macu-
lopathy following commencement of Docetaxel (Taxotere) with a
non-cystoid presentation. We advise that any patient started on
Docetaxel therapy should be counselled for possible drug asso-
ciated toxic maculopathy, and that this should be considered in all
patients complaining of visual disturbance. The Oncologist must
weigh the nature of the visual pathology and liaise the Ophthal-
mologist when managing such patients.Funding
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